Volume 65, Supplement 1:
Interleukin-6 in Rheumatoid Arthritis: A 2007 Update
Volume 65, Supplement 1:
Interleukin-6 in Rheumatoid Arthritis: A 2007 Update
| Introduction |
| Yusuf Yazici, M.D. |
| Abstract | View Full Article | PDF |
|
| Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis |
| Jean Y. Park, M.D., and Michael H. Pillinger, M.D. |
| Abstract | View Full Article | PDF |
|
| Interleukin-6 - A Key Mediator of Systemic and Local Symptoms in Rheumatoid Arthritis |
| Bruce N. Cronstein, M.D. |
| Abstract | View Full Article | PDF |
|
| Interleukin-6 Inhibition and Clinical Efficacy in Rheumatoid Arthritis Treatment - Data from Randomized Clinical Trials |
| Arthur Kavanaugh, M.D. |
| Abstract | View Full Article | PDF |
|
| Interleukin-6 Inhibition - Tolerability Profile and Clinical Implications |
| Vibeke Strand, M.D., and Yusuf Yazici, M.D. |
| Abstract | View Full Article | PDF |
|
| Monitoring Response to Treatment in Rheumatoid Arthritis - Which Tool is Best Suited for Routine “Real World” Care? |
| Yusuf Yazici, M.D. |
| Abstract | View Full Article | PDF |
|
| Patient Questionnaires and Formal Education as More Significant Prognostic Markers than Radiographs or Laboratory Tests for Rheumatoid Arthritis Mortality - Limitations of a Biomedical Model to Predict Long-Term Outcomes |
| Theodore Pincus, M.D. |
| Abstract | View Full Article | PDF |
|